Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy

被引:29
作者
Birk, M
Svedhem, V
Sönnerborg, A
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Div Clin Virol, S-14186 Huddinge, Sweden
[2] Huddinge Univ Hosp, Karolinska Inst, Div Infect Dis, S-14186 Huddinge, Sweden
[3] Karolinska Hosp, Div Infect Dis, S-10401 Stockholm, Sweden
关键词
antiretroviral therapy; drug resistance; HIV-1; rebound; viral load;
D O I
10.1097/00002030-200107270-00005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To study the kinetics of HIV-1 RNA and drug-induced mutations after cessation of anti retroviral therapy (ART). Design and methods: Successive plasma samples from 26 patients were tested for HIV-1 RNA by PCR and for mutations associated with drug resistance by sequencing of the pol gene. Results: After cessation of ART the phase of undetectable virus (< 50 copies/ml), ranging from 6 to more than 29 days, was followed by a rapid viral increase, which slowed down before a plateau corresponding to pre-treatment levels or higher was reached in most cases (14/19 patients). In one patient virus was still undetectable at 4 weeks. Also, a significantly larger number of primary protease inhibitor (PI)-associated mutations reverted to wild-type, as compared with secondary PI-, and primary reverse transcriptase inhibitor (RTI)-associated mutations. During the rapid viral increase no mutations disappeared, which instead happened during the slower viral increase preceding the viral plateau level. Conclusion: After discontinuation of ART large individual Variations were found for the time period until HIV-1 became detectable in plasma, possibly due to differences in the HIV-1 specific immunity. The more rapid loss of primary PI mutations suggests that they might cause a more impaired viral fitness than primary RTI mutations. However, the persistence of drug mutations during the initial viral load increase indicates that mutated strains may still replicate efficiently (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:1359 / 1368
页数:10
相关论文
共 36 条
[1]   PERSISTENCE OF AZIDOTHYMIDINE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA GENOTYPES IN POSTTREATMENT SERA [J].
ALBERT, J ;
WAHLBERG, J ;
LUNDEBERG, J ;
COX, S ;
SANDSTROM, E ;
WAHREN, B ;
UHLEN, M .
JOURNAL OF VIROLOGY, 1992, 66 (09) :5627-5630
[2]   Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users [J].
Alexander, CS ;
Dong, W ;
Schechter, MT ;
O'Shaughnessy, MV ;
Strathdee, SA ;
Mo, T ;
Montaner, JSG ;
Harrigan, PR .
AIDS, 1999, 13 (08) :981-985
[3]   Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients [J].
Birk, M ;
Sönnerborg, A .
AIDS, 1998, 12 (18) :2369-2375
[4]  
Birk M, 2000, HIV Med, V1, P205, DOI 10.1046/j.1468-1293.2000.00030.x
[5]   EFFECTS OF DISCONTINUATION OF ZIDOVUDINE TREATMENT ON ZIDOVUDINE SENSITIVITY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES [J].
BOUCHER, CAB ;
VANLEEUWEN, R ;
KELLAM, P ;
SCHIPPER, P ;
TIJNAGEL, J ;
LANGE, JMA ;
LARDER, BA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (07) :1525-1530
[6]  
Centers for Disease Control, 1993, MMWR Morb Mortal Wkly Rep, V41, P1
[7]   AIDS - Re-emergence of HIV after stopping therapy [J].
Chun, TW ;
Davey, RT ;
Engel, D ;
Lane, HC ;
Fauci, AS .
NATURE, 1999, 401 (6756) :874-875
[8]   HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression [J].
Davey, RT ;
Bhat, N ;
Yoder, C ;
Chun, TW ;
Metcalf, JA ;
Dewar, R ;
Natarajan, V ;
Lempicki, RA ;
Adelsberger, JW ;
Millers, KD ;
Kovacs, JA ;
Polis, MA ;
Walker, RE ;
Falloon, L ;
Masur, H ;
Gee, D ;
Baseler, M ;
Dimitrov, DS ;
Fauci, AS ;
Lane, HC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (26) :15109-15114
[9]   Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. [J].
Deeks, SG ;
Wrin, T ;
Liegler, T ;
Hoh, R ;
Hayden, M ;
Barbour, JD ;
Hellmann, NS ;
Petropoulos, CJ ;
McCune, JM ;
Hellerstein, MK ;
Grant, RM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07) :472-480
[10]   Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment [J].
deJong, MD ;
deBoer, RJ ;
deWolf, F ;
Foudraine, NA ;
Boucher, CAB ;
Goudsmit, J ;
Lange, JMA .
AIDS, 1997, 11 (11) :F79-F84